Background: this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic; Methods: we conducted a cross-sectional study on stored cryopreserved samples from 1 March 2020 to 30 November 2020. Total antibodies against SARS-CoV-2 were preliminarily tested using a chemiluminescent immunoassay. Positive results were re-tested with an ELISA assay as an IgG confirmatory test; Results: overall, 1389 samples were analyzed from 1106 PLWH: 69% males, median age 53 years, 94% on antiretroviral treatment, 93% with HIV-RNA < 50 copies/mL, median CD4 cell count 610 cell/µL. Our analysis revealed a total of n = 8 patients who tested IgG positive during the study period. Seroprevalence was equal to 0% in the first months (March–June); this started to increase in July and reached a maximum rate of 1.59% in October 2020. The overall seroprevalence was 0.72% (8/1106, 95% CI 0.37–1.42). Conclusion: our findings from this setting show a low IgG SARS-CoV-2 prevalence among PLWH as compared to data available from the general population.
【저자키워드】 COVID-19, SARS-CoV-2, HIV, Seroprevalence, Antiretroviral therapy, 【초록키워드】 Treatment, IgG, antibody, cross-sectional, Prevalence, Patient, second wave, General population, chemiluminescent immunoassay, PLWH, ELISA assay, Analysis, 95% CI, median age, study period, Rome, positive, large sample, antiretroviral, Italian, males, tested, analyzed, proportion, conducted, median, determine, increase in, reached, Total, with HIV, anti-SARS-CoV-2 IgG antibody, CD4 cell, 【제목키워드】 Italy, Rome,